Acutis Biosciences, a biomarker discovery provider, opened a state-of-the-art 60,000-square-foot facility in Monmouth Junction, NJ. The company also appointed Troy Tremaine as its Chief Commercial Officer.

Acutis Biosciences combines a multi-omics biomarker profiling approach with data integration to provide pharmaceutical and biotechnology companies with tools needed to help advance clinical discovery.

According to the company, this unique approach builds on the expertise gained through its standard-of-care business, Acutis Diagnostics, which has processed over three million patient samples over the past seven years with turnaround times that have been consistently at the top of the industry.  

In his new role, Tremaine will oversee commercial operations with an emphasis on collaboration and relentless dedication to clients’ success. Tremaine brings over 26 years of experience within the life sciences and CRO industry. His extensive experience includes fostering strategic partnerships, implementing customer-focused programs, and growing complex businesses.

Acutis CEO Jibreel Sarij said, “We are reimagining biomarker discovery at the intersection of DNA, RNA, and protein diagnostics and are rewriting the rules to champion our biopharma partners. Far too often, we have heard about the industry’s dissatisfaction with CROs, whether it be slow turnaround time, incomplete data analytics, or missed opportunities to advance drug discovery with robust biomarker analytics. Moreover, we are investing in the machine learning AI tools that will become increasingly important in the interpretation of the complex data sets that our multi-omics analyses will yield.”

Acutis Biosciences has developed specialized contract research services to enable biopharmaceutical companies to create value using a holistic approach to “next-generation multi-omics.” The company is rolling out the first set of genomic offerings along with immunohistochemistry assays and building out integrated analytics across DNA, RNA, protein, and broader multi-omics.